ROLE OF cfDNA AND ctDNA TO IMPROVE THE RISK STRATIFICATION AND THE DISEASE FOLLOW-UP IN PATIENTS WITH ENDOMETRIAL CANCER: TOWARDS THE CLINICAL APPLICATION
View ORCID ProfileCarlos Casas-Arozamena, Ana Vilar, Juan Cueva, View ORCID ProfileEfigenia Arias, Victoria Sampayo, Eva Diaz, View ORCID ProfileSara S Oltra, View ORCID ProfileCristian Pablo Moiola, View ORCID ProfileSilvia Cabrera, View ORCID ProfileAlexandra Cortegoso, View ORCID ProfileTeresa Curiel, View ORCID ProfileAlicia Abalo, Mónica Pamies Serrano, View ORCID ProfileSantiago Domingo del Pozo, Pablo Padilla-Iserte, View ORCID ProfileMarta Arnaez de la Cruz, View ORCID ProfileAlicia Hernández, Virginia García-Pineda, View ORCID ProfileJuan Ruiz Bañobre, View ORCID ProfileRafael López, View ORCID ProfileXavier Matias-Guiu, View ORCID ProfileEva Colás, View ORCID ProfileAntonio Gil-Moreno, View ORCID ProfileMiguel Abal, View ORCID ProfileGema Moreno-Bueno, View ORCID ProfileLaura Muinelo-Romay
doi: https://doi.org/10.1101/2024.05.20.24307623
Carlos Casas-Arozamena
1Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain
2University of Santiago de Compostela (USC), Praza do Obradoiro, 0, 15705 Santiago de Compostela, Spain
3Centro de Investigación Biomédica en Red de Cáncer (CIBERONC)
Ana Vilar
4Department of Gynecology, University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain
Juan Cueva
1Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain
5Department of Medical Oncology, University Clinical Hospital of Santiago de Compostela, University of Santiago de Compostela (USC), 15706 Santiago de Compostela, Spain
Efigenia Arias
4Department of Gynecology, University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain
Victoria Sampayo
4Department of Gynecology, University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain
Eva Diaz
6Foundation MD Anderson International, C/Gómez Hemans 2, 28033 Madrid, Spain
Sara S Oltra
6Foundation MD Anderson International, C/Gómez Hemans 2, 28033 Madrid, Spain
Cristian Pablo Moiola
7Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autónoma de Barcelona, 119-129 Pg. Vall d’Hebron, 08035 Barcelona, Spain
8Department of Basic Sciences. Faculty of Health Sciences at Manresa. University of Vic – Central University of Catalonia (UVic-UCC). Av. Universitària, 4-6, 08242 Manresa, Spain
Silvia Cabrera
7Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autónoma de Barcelona, 119-129 Pg. Vall d’Hebron, 08035 Barcelona, Spain
Alexandra Cortegoso
1Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain
5Department of Medical Oncology, University Clinical Hospital of Santiago de Compostela, University of Santiago de Compostela (USC), 15706 Santiago de Compostela, Spain
Teresa Curiel
1Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain
5Department of Medical Oncology, University Clinical Hospital of Santiago de Compostela, University of Santiago de Compostela (USC), 15706 Santiago de Compostela, Spain
Alicia Abalo
1Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain
Mónica Pamies Serrano
7Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autónoma de Barcelona, 119-129 Pg. Vall d’Hebron, 08035 Barcelona, Spain
Santiago Domingo del Pozo
9Department of Gynecologic Oncology. La Fe University and Polytechnic Hospital. Valencia. Spain
Pablo Padilla-Iserte
9Department of Gynecologic Oncology. La Fe University and Polytechnic Hospital. Valencia. Spain
Marta Arnaez de la Cruz
9Department of Gynecologic Oncology. La Fe University and Polytechnic Hospital. Valencia. Spain
Alicia Hernández
10Department of Gynecology, University Hospital “La Paz“, Madrid, Spain
Virginia García-Pineda
11Department of Pathology, Hospital U de Bellvitge and Hospital U Arnau de Vilanova, Universities of Lleida and Barcelona, Institut de Recerca Biomèdica de Lleida, Instituto de Investigación Biomédica de Bellvitge, Centro de Investigación Biomédica en Red de Cáncer, Barcelona, Spain
Juan Ruiz Bañobre
1Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain
3Centro de Investigación Biomédica en Red de Cáncer (CIBERONC)
5Department of Medical Oncology, University Clinical Hospital of Santiago de Compostela, University of Santiago de Compostela (USC), 15706 Santiago de Compostela, Spain
Rafael López
1Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain
2University of Santiago de Compostela (USC), Praza do Obradoiro, 0, 15705 Santiago de Compostela, Spain
3Centro de Investigación Biomédica en Red de Cáncer (CIBERONC)
5Department of Medical Oncology, University Clinical Hospital of Santiago de Compostela, University of Santiago de Compostela (USC), 15706 Santiago de Compostela, Spain
Xavier Matias-Guiu
3Centro de Investigación Biomédica en Red de Cáncer (CIBERONC)
10Department of Gynecology, University Hospital “La Paz“, Madrid, Spain
Eva Colás
3Centro de Investigación Biomédica en Red de Cáncer (CIBERONC)
7Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autónoma de Barcelona, 119-129 Pg. Vall d’Hebron, 08035 Barcelona, Spain
Antonio Gil-Moreno
3Centro de Investigación Biomédica en Red de Cáncer (CIBERONC)
7Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autónoma de Barcelona, 119-129 Pg. Vall d’Hebron, 08035 Barcelona, Spain
Miguel Abal
1Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain
2University of Santiago de Compostela (USC), Praza do Obradoiro, 0, 15705 Santiago de Compostela, Spain
3Centro de Investigación Biomédica en Red de Cáncer (CIBERONC)
Gema Moreno-Bueno
3Centro de Investigación Biomédica en Red de Cáncer (CIBERONC)
6Foundation MD Anderson International, C/Gómez Hemans 2, 28033 Madrid, Spain
12Biochemistry Department, Medicine Faculty, Universidad Autónoma de Madrid (UAM), C/Arturo Dupurier 4, 28029 Madrid-Spain
Laura Muinelo-Romay
1Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain
2University of Santiago de Compostela (USC), Praza do Obradoiro, 0, 15705 Santiago de Compostela, Spain
3Centro de Investigación Biomédica en Red de Cáncer (CIBERONC)
Article usage
Posted May 21, 2024.
ROLE OF cfDNA AND ctDNA TO IMPROVE THE RISK STRATIFICATION AND THE DISEASE FOLLOW-UP IN PATIENTS WITH ENDOMETRIAL CANCER: TOWARDS THE CLINICAL APPLICATION
Carlos Casas-Arozamena, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Eva Diaz, Sara S Oltra, Cristian Pablo Moiola, Silvia Cabrera, Alexandra Cortegoso, Teresa Curiel, Alicia Abalo, Mónica Pamies Serrano, Santiago Domingo del Pozo, Pablo Padilla-Iserte, Marta Arnaez de la Cruz, Alicia Hernández, Virginia García-Pineda, Juan Ruiz Bañobre, Rafael López, Xavier Matias-Guiu, Eva Colás, Antonio Gil-Moreno, Miguel Abal, Gema Moreno-Bueno, Laura Muinelo-Romay
medRxiv 2024.05.20.24307623; doi: https://doi.org/10.1101/2024.05.20.24307623
ROLE OF cfDNA AND ctDNA TO IMPROVE THE RISK STRATIFICATION AND THE DISEASE FOLLOW-UP IN PATIENTS WITH ENDOMETRIAL CANCER: TOWARDS THE CLINICAL APPLICATION
Carlos Casas-Arozamena, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Eva Diaz, Sara S Oltra, Cristian Pablo Moiola, Silvia Cabrera, Alexandra Cortegoso, Teresa Curiel, Alicia Abalo, Mónica Pamies Serrano, Santiago Domingo del Pozo, Pablo Padilla-Iserte, Marta Arnaez de la Cruz, Alicia Hernández, Virginia García-Pineda, Juan Ruiz Bañobre, Rafael López, Xavier Matias-Guiu, Eva Colás, Antonio Gil-Moreno, Miguel Abal, Gema Moreno-Bueno, Laura Muinelo-Romay
medRxiv 2024.05.20.24307623; doi: https://doi.org/10.1101/2024.05.20.24307623
Subject Area
Subject Areas
- Addiction Medicine (373)
- Allergy and Immunology (690)
- Anesthesia (184)
- Cardiovascular Medicine (2760)
- Dermatology (236)
- Emergency Medicine (414)
- Epidemiology (12413)
- Forensic Medicine (10)
- Gastroenterology (784)
- Genetic and Genomic Medicine (4272)
- Geriatric Medicine (396)
- Health Economics (702)
- Health Informatics (2761)
- Health Policy (1021)
- Hematology (370)
- HIV/AIDS (880)
- Medical Education (404)
- Medical Ethics (112)
- Nephrology (454)
- Neurology (4054)
- Nursing (218)
- Nutrition (600)
- Oncology (2134)
- Ophthalmology (607)
- Orthopedics (251)
- Otolaryngology (313)
- Pain Medicine (256)
- Palliative Medicine (77)
- Pathology (479)
- Pediatrics (1150)
- Primary Care Research (470)
- Public and Global Health (6663)
- Radiology and Imaging (1453)
- Respiratory Medicine (886)
- Rheumatology (422)
- Sports Medicine (353)
- Surgery (465)
- Toxicology (57)
- Transplantation (192)
- Urology (171)